What Is PANS Syndrome? Symptoms, Causes & Treatment

Pediatric acute-onset neuropsychiatric syndrome, or PANS, is a clinical diagnosis describing children who develop sudden, severe obsessive-compulsive symptoms or eating restrictions alongside a cluster of other psychiatric and neurological changes, all appearing within about 48 hours. Unlike the gradual worsening that characterizes most childhood mental-health conditions, the hallmark of PANS is speed: a child who seemed fine on Monday may be unrecognizable by Wednesday. The condition remains one of the more contested diagnoses in pediatric medicine, with genuine disagreement among specialists about its underlying mechanisms, its boundaries, and even whether it constitutes a distinct disease entity at all.

How PANS Is Defined

The PANS criteria were proposed as a broadening of an earlier concept called PANDAS (pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections). PANDAS linked acute-onset OCD and tics specifically to strep throat, but clinicians noticed similar dramatic presentations in children with no evidence of strep. PANS drops the strep requirement and instead defines the syndrome purely by its clinical picture. The formal criteria require an abrupt, dramatic onset of OCD or severely restricted food intake, developing in under 48 hours, plus at least two additional neuropsychiatric symptoms from a defined list.

Those additional symptoms span a wide range:

Anxiety: often extreme separation anxiety or new fears that seem to appear out of nowhere
Emotional lability or depression: rapid mood swings, uncontrollable crying, or sudden sadness
Irritability and aggression: severe oppositional behavior that is out of character for the child
Behavioral regression: a child who was age-appropriate may start behaving years younger, including baby talk or clinginess
Academic deterioration: sudden drop in school performance, sometimes within days
Sensory or motor abnormalities: heightened sensitivity to light, sound, or touch; new tics; deteriorating handwriting (dysgraphia); or even hallucinations
Somatic symptoms: new-onset bedwetting, frequent urination, or serious sleep disturbances

The speed and breadth of these changes are what distinguish PANS from a typical psychiatric presentation. A child might develop crippling OCD rituals, lose the ability to write legibly, start wetting the bed, and become terrified of being separated from a parent, all within a matter of days.

The Role of Eating Restrictions

One feature that surprises many parents and clinicians is that severely restricted eating can be the primary presenting symptom instead of OCD. Children with PANS may suddenly refuse to eat, sometimes based on contamination fears (a form of OCD), but other times for reasons that are harder to categorize, such as fear of choking, distorted body image, or sensory aversion to textures they previously tolerated. Research has confirmed that sudden, clinically significant eating restrictions are a defining feature in some PANS cases, and this can be the symptom that first brings a child to medical attention, sometimes before anyone recognizes the other neuropsychiatric changes unfolding alongside it.¹

What Causes PANS

The short answer is that no one is entirely certain, and that uncertainty is a major part of the controversy. The leading hypothesis is that an infection or other immune trigger sets off a misdirected immune response that affects the brain, particularly the basal ganglia, a set of structures involved in movement, habit formation, and emotional regulation. In the original PANDAS framework, the trigger was group A streptococcus (the bacteria behind strep throat), and the proposed mechanism was molecular mimicry: the immune system generates antibodies to fight the strep bacteria, but those antibodies also react with proteins on brain cells because certain strep surface proteins resemble neuronal targets.²

PANS broadens the trigger beyond strep. Various infections have been implicated, including Mycoplasma pneumoniae (the bacterium behind “walking pneumonia”), influenza, and other common childhood infections.³ Some researchers have also proposed that non-infectious environmental factors, including oxidative stress, toxin exposure, and even severe emotional stress, could activate innate immune pathways and initiate abnormal inflammatory responses in children who are genetically susceptible. Genomic research has pointed to ultra-rare genetic variants in immune-signaling pathways, particularly those involving the NF-κB complex, a master regulator of inflammation, as possible contributors to this vulnerability.⁴

At the cellular level, researchers working with animal models have identified several mechanisms that could explain how immune activation translates into neuropsychiatric symptoms. These include disrupted dopamine release in the basal ganglia, abnormal activation of certain signaling enzymes in neurons, and dysfunction of specific interneurons in the striatum.⁵ Imaging studies comparing patients with healthy controls have also found evidence of inflammation in the basal ganglia, and sleep studies have shown abnormal movements during REM sleep consistent with basal ganglia dysfunction.⁶

Why PANS Remains Controversial

Despite more than two decades of research since the PANDAS concept was first described in 1998, core questions remain unresolved. There is genuine, substantial disagreement among experienced clinicians and researchers about whether inflammation plays a direct role in producing OCD and tics in these children, and if it does, how best to treat it.⁷ The autoimmune hypothesis for PANDAS has not been definitively proven, and the broader PANS framework, which loosens the connection to any specific trigger, raises even more questions about what holds the diagnosis together as a coherent entity.⁸

Critics worry that the PANS label may be applied too freely to children who have sudden-onset psychiatric symptoms for a variety of reasons, potentially leading families toward immunological treatments that carry real risks and lack strong evidence. Proponents counter that dismissing the pattern means these children get only standard psychiatric care, which may not address an underlying immune-driven process. Both sides agree that better research is needed.

Diagnosis and the Problem With Testing

PANS is a clinical diagnosis, meaning there is no blood test or brain scan that confirms it. Clinicians diagnose it based on the pattern of symptoms: the sudden onset, the specific combination of neuropsychiatric features, and the exclusion of other conditions that could explain the picture. Standard workup typically involves checking for active infections, basic inflammatory markers, and ruling out conditions like autoimmune encephalitis.

One commercially available test, the Cunningham Panel, measures levels of certain anti-neuronal antibodies and their ability to stimulate neuronal cell activity. One study did find a positive association between changes in these antibody levels and changes in neuropsychiatric symptoms, suggesting potential clinical utility in monitoring.⁹ However, an independent evaluation found the panel’s performance to be poor: individual biomarker sensitivities ranged from only 15 to 60 percent, specificities from 28 to 92 percent, and a majority of healthy control subjects actually had results the panel would flag as abnormal. That study concluded that clinical use of the Cunningham Panel in diagnosing PANS or PANDAS is not supported.¹⁰ This is a good example of the conflicting evidence that makes PANS so frustrating for families: one study says a test might help, another says it produces too many false positives to be useful.

How PANS Differs From Autoimmune Encephalitis

A question that comes up frequently is whether PANS is just a form of autoimmune encephalitis (AE), a better-established condition in which the immune system attacks brain tissue. The two can look somewhat similar on the surface, since both involve acute neuropsychiatric symptoms and may involve abnormal immune responses. But a 2024 clinical report in Pediatrics draws clear distinctions. Children with AE tend to present with seizures, complex movement disorders, and focal neurological signs, along with evidence of central nervous system inflammation visible on MRI or in cerebrospinal fluid. PANS patients typically do not show these findings. AE symptoms also persist over time, whereas PANS characteristically follows a relapsing-remitting course with flares and periods of improvement. Perhaps the most useful clinical distinction is cognitive: the vast majority of children with AE show some degree of cognitive impairment on formal testing, while most children with PANS demonstrate normal cognition.¹¹

Treatment Approaches

Treatment for PANS typically involves a combination of strategies aimed at addressing any underlying infection, calming the immune response, and managing the psychiatric symptoms directly. The evidence base for all of these approaches is thin. A systematic review of PANDAS and PANS treatments found that rigorously conducted research is scarce and published studies carry a high risk of bias.¹² Another systematic review found very low certainty of evidence for beneficial effects of anti-inflammatory, antibacterial, or immunomodulating treatments, alongside moderate certainty that such treatments can produce adverse effects.¹³ That does not mean these treatments never help, but it does mean the evidence neither firmly supports nor firmly excludes benefit, and there are real risks involved.

Antibiotics

When an active infection is identified, treating it is straightforward and uncontroversial. The more debated practice is prophylactic antibiotics, where a child takes ongoing low-dose antibiotics to prevent future strep or other infections from triggering flares. Case reports have described adolescents treated with azithromycin prophylaxis to prevent clinical deterioration after PANDAS flares.¹⁴ But this remains based on clinical experience and case-level evidence, not randomized trials.

Anti-Inflammatory Medications

Over-the-counter anti-inflammatory drugs like ibuprofen and naproxen have drawn interest because they are low-risk and widely available. An observational study from a PANS specialty clinic found that flares treated with NSAIDs lasted meaningfully shorter: flares not treated with NSAIDs lasted roughly 12 weeks on average, while those managed with NSAIDs started within 30 days of flare onset were about two and a half weeks shorter. Children already on maintenance NSAID therapy when a flare hit saw their flares cut by about four weeks compared to untreated flares.¹⁵

Oral corticosteroid bursts have also been studied. In another observational study from the same clinic, patients treated with corticosteroids experienced flares lasting about six weeks on average, compared to roughly 11 weeks for untreated flares. Earlier use and longer courses of corticosteroids were both associated with shorter flare durations.¹⁶ These are observational findings, not randomized controlled trials, so they cannot prove the treatments caused the improvement, but they are consistent with the theory that reducing inflammation helps.

Intravenous Immunoglobulin

IVIG, a treatment that delivers pooled antibodies from donor blood to modulate the immune system, is one of the more aggressive interventions used in PANS. A case series of 12 youths treated with IVIG for PANDAS provided some of the first descriptions of long-term outcomes and suggested short-term benefits.¹⁷ A later open-label trial of IVIG in ten children with PANS found marked reductions in symptom severity scores, with nine out of ten children meeting criteria for clinical response. Improvements showed up in OCD scores, overall functioning, and school attendance.¹⁸ But open-label trials with ten participants cannot establish whether a treatment truly works or whether improvement reflects the natural waxing and waning of the illness. IVIG is also expensive, requires IV infusion, and carries potential side effects ranging from headache to rare but serious reactions.

Psychiatric and Behavioral Therapies

Regardless of whether the immune-mediated hypothesis is correct, the psychiatric symptoms are real and debilitating, and they respond to many of the same interventions used for OCD and anxiety in other children. Cognitive behavioral therapy, specifically exposure and response prevention, is considered one of the most effective treatments for the OCD component. Pilot studies suggest it works in children with PANS as well, though there is a catch: during acute flares, a child may be too overwhelmed by anxiety, sensory sensitivities, or cognitive fog to participate fully. Clinicians experienced with PANS recommend starting therapy as soon as the child is able, while in the meantime teaching parents strategies to avoid inadvertently reinforcing OCD behaviors through accommodation.¹⁹

Psychiatric medications such as SSRIs (the standard drugs for pediatric OCD) can also help, but clinical experience suggests children with PANS may be more sensitive to side effects, including agitation and dystonia. The standard advice from PANS-experienced clinicians is to start at a quarter or less of the typical dose and increase slowly.¹⁹

Long-Term Outlook

The course of PANS varies widely. A follow-up study tracking a cohort of 34 children over two to five years found that the most common pattern was relapsing-remitting: periods of flare alternating with periods of significant improvement. Two patients achieved full remission, 20 followed the relapsing-remitting pattern, and 12 had a chronic or progressive course. The children with chronic symptoms tended to have an earlier age of onset, greater impairment, and needed more treatment. The overall picture was cautiously encouraging, since the majority of children improved over the follow-up period, but a meaningful minority did not.²⁰

This relapsing-remitting pattern is one of the most important things for families to understand. A child may improve dramatically for months, then flare again after a new illness, leading parents to feel like they are back at square one. Knowing that this pattern is expected can help families plan rather than panic during setbacks.

The Impact on Families and Schools

PANS does not just affect the diagnosed child. Research on caregivers paints a stark picture: in a survey of over 200 caregivers of children with PANS, roughly 80 percent exceeded thresholds indicating need for respite support, about 73 percent reported high distress, and over 80 percent described feeling overwhelmed. Nearly 60 percent reported crying spells. The qualitative themes that emerged included severe family emotional distress, caregivers wondering what had happened to their child, lack of awareness among healthcare and education professionals, relationship strain, and financial struggles tied to the diagnosis.²¹

Schools often struggle too. Parents of children with PANS or PANDAS have reported declines in attendance, academic performance, and behavioral functioning. Because the condition can wax and wane unpredictably and because many educators have never heard of it, getting appropriate accommodations can be a lengthy battle.²² Children who were previously strong students may suddenly need modified assignments, extra time, or shortened school days during flares, then return to near-normal functioning during remission. That inconsistency makes it hard for schools to develop stable support plans.

What Happens When PANS Children Grow Up

Most of the research and clinical attention around PANS focuses on childhood, but the condition does not always resolve before adulthood. An interview study of young adults who had lived with PANS found a group that was largely isolated, still dependent on care from relatives, and still experiencing the illness as a tangible presence in their daily lives. These young adults described a lack of knowledge about PANS among adult healthcare providers, a feeling of being passed around the system without anyone taking responsibility for their treatment, and frustration that their own experience-based understanding of their illness was frequently dismissed in clinical encounters.²³

The transition from pediatric to adult care is a known weak point. Because PANS is defined as a pediatric condition and many adult psychiatrists and neurologists are unfamiliar with it, young adults can find themselves without a clinician who understands their history. For families navigating this transition, connecting with a PANS-knowledgeable provider before the child ages out of pediatric care is worth pursuing early.